Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Frontiers in Cardiovascular Medicine|July 10, 2024
Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarctionMaxime Nguyen, Alain Putot, David Masson, et al.
Journal of Clinical Lipidology|September 15, 2020
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trialEli M Roth, John J P Kastelein, Christopher P Cannon, et al.
Journal of Clinical Lipidology|November 12, 2019
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg dosesJennifer G Robinson, Michel Farnier, John J P Kastelein, et al.
European Journal of Human Genetics : EJHG|January 28, 2018
Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?Youmna Ghaleb, Sandy Elbitar, Petra El Khoury, et al.
International Journal of Cardiology|December 3, 2014
Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patientsMarta Michalska-Kasiczak, Amirhossein Sahebkar, Dimitri P Mikhailidis, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
The New England Journal of Medicine|March 17, 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular eventsJennifer G Robinson, Michel Farnier, Michel Krempf, et al.
Journal of Clinical Lipidology|August 5, 2019
Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studiesFrederick J Raal, Jaakko Tuomilehto, Andrei C Sposito, et al.
Atherosclerosis|April 24, 2021
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task ForceMaurizio Averna, Maciej Banach, Eric Bruckert, et al.
The Journal of Pediatrics|September 1, 2022
Factors Predicting Statin Initiation During Childhood in Familial Hypercholesterolemia: Importance of Genetic DiagnosisNoel Peretti, Alexandre Vimont, Emmanuel Mas, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Frontiers in Cardiovascular Medicine|July 10, 2024
Risk factors and prognostic value of endotoxemia in patients with acute myocardial infarctionMaxime Nguyen, Alain Putot, David Masson, et al.
Journal of Clinical Lipidology|September 15, 2020
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trialEli M Roth, John J P Kastelein, Christopher P Cannon, et al.
Journal of Clinical Lipidology|November 12, 2019
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg dosesJennifer G Robinson, Michel Farnier, John J P Kastelein, et al.
European Journal of Human Genetics : EJHG|January 28, 2018
Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?Youmna Ghaleb, Sandy Elbitar, Petra El Khoury, et al.
International Journal of Cardiology|December 3, 2014
Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patientsMarta Michalska-Kasiczak, Amirhossein Sahebkar, Dimitri P Mikhailidis, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
The New England Journal of Medicine|March 17, 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular eventsJennifer G Robinson, Michel Farnier, Michel Krempf, et al.
Journal of Clinical Lipidology|August 5, 2019
Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studiesFrederick J Raal, Jaakko Tuomilehto, Andrei C Sposito, et al.
Atherosclerosis|April 24, 2021
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task ForceMaurizio Averna, Maciej Banach, Eric Bruckert, et al.
The Journal of Pediatrics|September 1, 2022
Factors Predicting Statin Initiation During Childhood in Familial Hypercholesterolemia: Importance of Genetic DiagnosisNoel Peretti, Alexandre Vimont, Emmanuel Mas, et al.
Pageof 15